WCM-Q Grand Rounds 'Diagnosis and Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)'

RSSAMADHPWebinar

Add to Calendar WCM-Q Grand Rounds 'Diagnosis and Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)' 12/10/2023 3:30:00 PM 12/10/2023 4:30:00 PM Asia/Riyadh For More Details: https://wcmq.cloud-cme.com/course/courseoverview?EID=2356 Description: Date:Sunday, December 10, 2023Speaker:Sara Saleh Al-Khawaga, MD, PhDLearning Objectives:At the end of this activity, participants will be able to1.Describe the Diagnostic criteria for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)2.List the Pathogenesis/mechanisms of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)3.Describe the Clinical characteristics of Stevens-Johnson synd... Livestream (Zoom) false MM/DD/YYYY


Date & Location
Sunday, December 10, 2023, 3:30 PM - 4:30 PM, Livestream (Zoom)

Overview

Date: Sunday, December 10, 2023

Speaker: Sara Saleh Al-Khawaga, MD, PhD

Learning Objectives:

At the end of this activity, participants will be able to

1. Describe the Diagnostic criteria for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

2. List the Pathogenesis/mechanisms of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

3. Describe the Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

4. Summarize the Management of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

5. Describe Qatar’s epidemiology data and describe the National Clinical Practice Guidelines on Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)


 

To be able to register for the activity you MUST first Sign In to the portal.

The registration closes ONE day before the activity. You will receive a UNIQUE link to join the webinar on the day of the presentation.

 



Target Audience
Specialties - Allied Health Professionals, Dentists, Nurses, Pharmacists, Physicians, Students

Overall Learning Objective
  1. Describe the Diagnostic criteria for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
  2. List the Pathogenesis/mechanisms of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
  3. Describe the Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
  4. Summarize the Management of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)
  5. Describe Qatar’s epidemiology data and describe the National Clinical Practice Guidelines on Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

Registration
No Registration Fee

Accreditation

 

 

 

Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Department of Healthcare Professions (DHP) of the Ministry of Public Health.

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Ministry of Public Health's Department of Healthcare Professions-Accreditation Section and is approved for a maximum of 1 hour. 

 

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Relationships/Content Validity

It is the policy of Weill Cornell Medicine-Qatar to adhere to the Ministry of Public Health's Department of Healthcare Professions (DHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias. 

Scientific Planning Committee: Tariq Chukir, MD, Thurayya Arayssi, MD, Sohaila Cheema, MBBS, Deema Al-Sheikhly, MRes, MEPH, Sheila Qureshi, PhD, Christopher Triggle, PhD, Maria Paiva, PharmD, Andrew Jones, BSN, Phyllis Sui Muffuh Navti, Doctorate in Pharmacy Practice, Reshma Bholah, MD, Constatina Dalassou, DDS, Devin Thompson, RT, have no relevant financial relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

Jamie M. Gray, MLS, MS has disclosed the following relationships:Stock Shareholder - Proctor & Gamble;Colgate-Palmolive

Faculty: Sara Saleh Al-Khawaga, MD, PhD, has no relevant financial relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.  

Administrative Contacts: Asha Fernandes has no relevant financial relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

ICR: Tariq Chukir, MD, has no relevant financial relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.